Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeuti BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE ...
Pyxis Tankers – Continued Focus On Shareholder Returns With Diversification Into The Dry Bulk Sector Capital Link President Nicolas Bornozis recently hosted an interview with Mr. Eddie Valentis ...
These tables present gross rates in U.S.$ and do not reflect any commissions payable. “Pyxis Theta” is fixed on a time charter for 12 months +/- 30 days, at $22,000 per day. “Pyxis Karteria ...
The completion of the $3.0 million common share repurchase program demonstrates Pyxis Tankers' commitment to returning value to shareholders and potentially enhancing share price. Redemption of ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
Maroussi, Greece – January 30, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback